We previously reported that VEGF and inflammatory factors may contribute to the pathogenesis of macular edema associated with BRVO [6-9], which provides a rationale supporting the efficacy of intravitreal triamcinolone (IVTA) and anti-VEGF therapy. Here, VEGFA is linked to macular retinal edema.